Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Merck & Co. and Samsung Bioepis to develop insulin glargine candidate

Feb. 12, 2014

Sprout Pharmaceuticals receives clear guidance from FDA on flibanserin

Feb. 12, 2014

Kareus Therapeutics cleared to begin phase I trial of KU-5039 in diabetes

Feb. 12, 2014

Oramed submits phase IIa protocol to FDA for oral insulin capsule

Feb. 11, 2014

Lipocine begins dosing in pivotal SOAR study

Feb. 11, 2014

Study of Repros' Androxal shows sustained effect in men with secondary hypogonadism

Feb. 11, 2014

Merck & Co. reports development of DPP IV inhibitors for diabetes

Feb. 11, 2014

First-in-human clinical evaluation of a sustained-release exenatide for the treatment of diabetes

Feb. 11, 2014

Metabrain Research divulges compounds with potential for treatment of type 2 diabetes

Feb. 10, 2014

Chinese researchers patent novel CETP inhibitors

Feb. 10, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent
BioWorld Science
Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral...